{
  "id": "nsclc-pd1-by-payer",
  "display_name": "NSCLC PD-L1≥50% (By Payer)",
  "cohort": "NSCLC PD-L1 ≥ 50%, First Line, by Payer, Q1 2023",
  "insight_type": "Treatment Patterns by Payer",
  "summary": "Pembrolizumab monotherapy utilization varies by payer, with Medicare patients receiving guideline-concordant care at 82% while Commercial patients are at only 68%.",
  "recommendation": "Address payer-specific barriers to pembrolizumab monotherapy, particularly focusing on commercial payers.",
  "financial_impact": {
    "annual_opportunity": "$210,000/year",
    "math": "Improving pembrolizumab monotherapy utilization in patients with commercial insurance could generate approximately $210,000 in annual savings."
  },
  "financial_impact_description": "Improving pembrolizumab monotherapy utilization in patients with commercial insurance could generate approximately $210,000 in annual savings.",
  "peer_financial_impact": 250000,
  "peer_financial_impact_description": "Peer organizations achieve better utilization with commercial payers, representing a $250,000 opportunity.",
  "action_steps": [
    {
      "text": "Analyze approval rates and rejection reasons for pembrolizumab monotherapy by commercial payers",
      "icon": "chart-bar"
    },
    {
      "text": "Develop payer-specific prior authorization support",
      "icon": "user-group"
    },
    {
      "text": "Review testing and referral patterns for commercially insured patients",
      "icon": "star"
    }
  ],
  "peer_action_steps": [
    "Benchmark against organizations with higher commercial payer utilization",
    "Consider value-based contracts that incentivize appropriate care",
    "Develop specific strategies for working with challenging payers"
  ],
  "chart_data": {
    "categories": [
      "Medicare",
      "Commercial",
      "Medicaid",
      "Uninsured",
      "Other"
    ],
    "values": [
      82,
      68,
      75,
      70,
      72
    ],
    "peer_values": [
      85,
      80,
      78,
      70,
      75
    ],
    "target_values": [
      85,
      85,
      85,
      75,
      80
    ]
  },
  "drilldowns": [],
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      {
        "name": "Medicare",
        "value": 82,
        "gap": 0,
        "highlight": true
      },
      {
        "name": "Commercial",
        "value": 68,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Medicaid",
        "value": 75,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Uninsured",
        "value": 70,
        "gap": 0,
        "highlight": false
      },
      {
        "name": "Other",
        "value": 72,
        "gap": 0,
        "highlight": false
      }
    ],
    "benchmark": 65,
    "nccn_target": 65
  },
  "clinical_impact": {
    "description": "Clinical impact analysis based on outcomes data and peer-reviewed literature.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+3.2 months",
        "description": "Potential median progression-free survival improvement"
      },
      {
        "type": "OS",
        "value": "+5.1 months",
        "description": "Potential median overall survival improvement"
      },
      {
        "type": "QoL",
        "value": "+15%",
        "description": "Enhanced quality of life measures"
      }
    ],
    "quantitative": "+5.1 months OS"
  },
  "weighted_score": 94
}